Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Schiff, R"'
Autor:
Hariprasad Thangavel, Rachel Schiff, Sarmistha Nanda, Meghana V. Trivedi, Suhas Vasaikar, Bing Zhang, Carmine De Angelis, Martin Shea, Raksha Bhat, Ambily Gopinathan, Lanfang Qin, Tamika Mitchell, Noor Mazin Abdulkareem
Publikováno v:
FASEB J
While G protein-coupled receptors (GPCRs) are known to be excellent drug targets, the second largest family of adhesion-GPCRs is less explored for their role in health and disease. ADGRF1 (GPR110) is an adhesion-GPCR and has an important function in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1978c6f1b6b1ab1102718017162bc67f
https://europepmc.org/articles/PMC8218746/
https://europepmc.org/articles/PMC8218746/
Autor:
Aranzazu Fernandez-Martinez, Barbara Adamo, Blanca Gonzalez-Farre, Lisa A. Carey, Francesco Schettini, Benedetta Conte, Charles M. Perou, Jamunarani Veeraraghavan, Jan C. Brase, Sabino De Placido, Tomás Pascual, Mariavittoria Locci, Pierfranco Conte, Patricia Villagrasa, Montserrat Muñoz, Sonia Pernas, Fara Brasó-Maristany, Olga Martínez, Patricia Galván, Maria Vidal, Mothaffar F. Rimawi, C. Kent Osborne, Carla Rognoni, Gaia Griguolo, Rachel Schiff, Nuria Chic, Valentina Guarneri, Aleix Prat
Publikováno v:
Cancer Treat Rev
Background: HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be associated with higher pathological complete response (pCR) rates following anti-HER2-based reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456360a8625da925d93580bf31f87b0f
https://europepmc.org/articles/PMC7230134/
https://europepmc.org/articles/PMC7230134/
Autor:
C. Kent Osborne, Vidyalakshmi Sethunath, Rachel Schiff, Mothaffar F. Rimawi, Jamunarani Veeraraghavan, Carmine De Angelis, Kristina Goutsouliak
Publikováno v:
Nat Rev Clin Oncol
Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast cancer. The standard-of-care treatment for localized disease has been chemotherapy and 1 year of adjuvant HER2-targeted therapy, typically with the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b7964be3e4fdc804b203e88021196b
http://hdl.handle.net/11588/847721
http://hdl.handle.net/11588/847721
Autor:
Britta Weigelt, Anne Pavlick, C. Kent Osborne, Marilyn M. Li, Kathleen A. Burke, Jorge S. Reis-Filho, Tao Wang, Fresia Pareja, Matthew P. Goetz, Rachel Schiff, Jenny C. Chang, Rita Nanda, Suzanne A. W. Fuqua, Carmine De Angelis, Ian E. Krop, Ingrid A. Mayer, Mothaffar F. Rimawi, Sabrina Herrera, Antonio C. Wolff, Andres Forero, Felipe C Geyer, Alejandro Contreras, Susan G. Hilsenbeck, Carolina Gutierrez
Publikováno v:
Breast Cancer Research and Treatment. 167:731-740
Aberrant activation of the PI3K pathway has been implicated in resistance to HER2-targeted therapy, but results of clinical trials are confounded by the co-administration of chemotherapy. We investigated the effect of perturbations of this pathway in
Autor:
Dharmendra K. Bhargava, P Yadav, Vihang A. Narkar, Debashish Sahay, Raksha Bhat, Carmine De Angelis, Meghana V. Trivedi, Vikas Yadav, Sahar Yazdanfard, Ahmed Al-rawi, C. Kent Osborne, Lanfang Qin, Xiaoyong Fu, Chad J. Creighton, Sarmistha Nanda, Vidyalakshmi Sethunath, Rachel Schiff
PURPOSE: G protein-coupled receptors (GPCRs) represent the largest family of druggable targets in human genome. Although several GPCRs can cross-talk with the human epidermal growth factor receptors (HERs), the expression and function of most GPCRs r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8f707e8f16613b2296e9823e8de198b
http://hdl.handle.net/11588/776667
http://hdl.handle.net/11588/776667
Autor:
Sabrina Herrera, Meghana V. Trivedi, Sufeng Mao, Mario Giuliano, Joe W. Gray, Carmine De Angelis, Sara López-Tarruella, Huizhong Hu, Laura M. Heiser, Yen-Chao Wang, C. Kent Osborne, Rachel Schiff, Nicholas J. Wang, Mothaffar F. Rimawi, Anne Pavlick, Agostina Nardone, Jenny C. Chang, Alejandro Contreras, Susan G. Hilsenbeck, Gary C. Chamness, Xiaoyong Fu, Tao Wang, Carolina Gutierrez
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Purpose: To investigate the direct effect and therapeutic consequences of epidermal growth factor receptor 2 (HER2)-targeting therapy on expression of estrogen receptor (ER) and Bcl2 in preclinical models and clinical tumor samples. Experimental desi
Autor:
C. Kent Osborne, Carmine De Angelis, Jorge S. Reis-Filho, Jamunarani Veeraraghavan, Aleix Prat, Mothaffar F. Rimawi, Rachel Schiff, Tomás Pascual
Overexpression and/or gene amplification of HER2, a crucial member of the HER family of four receptors, occur in about 15-20% of breast cancers and define an aggressive subtype of the disease. Activated HER homo and heterodimers govern a complex and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91fc5b38c62a2a02712292d649c32db7
https://europepmc.org/articles/PMC6050048/
https://europepmc.org/articles/PMC6050048/
Autor:
Kathleen A. Burke, Ian Waters, Agostina Nardone, Joe W. Gray, Martin Shea, Ben Ho Park, Carmine De Angelis, Sarmistha Nanda, Chandandeep Nagi, Daniel J. Zabransky, Mahitha Rajendran, Jamunarani Veeraraghavan, Felipe C Geyer, Tamika Mitchell, Carolina Gutierrez, Huizhong Hu, Gary C. Chamness, Britta Weigelt, C. Kent Osborne, Jorge S. Reis-Filho, Nicholas J. Wang, Vidyalakshmi Sethunath, Kenneth L. Scott, Rachel Schiff, Lanfang Qin, Xiaowei Xu, Alexander Renwick, Susan G. Hilsenbeck, Laura M. Heiser, Mothaffar F. Rimawi, Edward S. Chen, Chad A. Shaw, Charlotte K.Y. Ng, Tao Wang
Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of alternative survival pathways or reactivation of the HER signaling network. Here we employed BT474 parental and treatment-resistant cell line models to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb068280b301594f2965d31acd31789
https://europepmc.org/articles/PMC5762201/
https://europepmc.org/articles/PMC5762201/
Autor:
C. Kent Osborne, Martin Shea, Tao Wang, Xiaoyong Fu, Gladys Morrison, Rachel Schiff, Sarmistha Nanda, Teresa Klinowska, Mothaffar F. Rimawi, Mario Giuliano
Modest up-regulation of either HER-ligands or receptors has been implicated in acquired endocrine resistance. AZD8931, a dual tyrosine kinase inhibitor (TKI) of epithelial growth factor receptor (EGFR)/HER2, has been shown to more effectively block l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3746f6a9bdd18e8f00219647ab300dc9
http://hdl.handle.net/11588/575194
http://hdl.handle.net/11588/575194
Autor:
Ilenia Migliaccio, Robin Ward, Meng-Fen Wu, Susan G. Hilsenbeck, Carolina Gutierrez, Grazia Arpino, Yen-Chao Wang, Rachel Schiff, C. Kent Osborne, Mothaffar F. Rimawi, Suleiman Massarweh, Catherine Huang, Robert D Soliz, Lisa Wiechmann
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(6)
Purpose: We have shown that incomplete blockade of the human epidermal growth factor (HER) pathway is a mechanism of resistance to treatment with trastuzumab (T) in HER2-overexpressing tumor xenografts. We now investigate whether the addition of lapa